1 / 34

Kevin B. Jones, MD Charles Searby, BS Gail Kurriger, BS James Martin, PhD Peter J. Roughley, PhD

Osteochondromagenesis: Loss of heterozygosity modeled via Cre-mediated inversion of the second exon of Ext1 in chondrocytes. Department of Orthopaedics and Rehabilitation University of Iowa Hospitals & Clinics. Kevin B. Jones, MD Charles Searby, BS Gail Kurriger, BS James Martin, PhD

Download Presentation

Kevin B. Jones, MD Charles Searby, BS Gail Kurriger, BS James Martin, PhD Peter J. Roughley, PhD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Osteochondromagenesis:Loss of heterozygosity modeled via Cre-mediated inversion of the second exon of Ext1 in chondrocytes Department of Orthopaedics and Rehabilitation University of Iowa Hospitals & Clinics Kevin B. Jones, MD Charles Searby, BS Gail Kurriger, BS James Martin, PhD Peter J. Roughley, PhD Jose A. Morcuende, MD, PhD Joseph A. Buckwalter, MD, MS Val C. Sheffield, MD, PhD Connective Tissue Oncology Society London, UK Friday, 14 November 2008

  2. Human EXT1:What is known clinically. . . Hereditary Multiple Exostosis • Autosomal dominant inheritance • Shortened long bones • Multiple osteochondromas • Homozygosity lethal

  3. EXT1 & EXT2:Tumor Supressor Genes? • Loss of heterozygosity in chondrocytes of cartilage cap of HME osteochondromas • Both alleles somatically mutated in some solitary osteochondromas Raskind et al. 1995; Bovee et al. 1999; Hecht et al. 1995 and 1997.

  4. Ext1 Knock-Out Mice by Lin et al. 2000Mouse Ext1 has 99% Homology to Human EXT1 PROBLEMS: • Homozygous Ext1-knock-out mice do not survive to birth • Heterozygous Ext1-knock-out mice very rarely form osteochondromas Simlar with Ext2 knock-out mice, Sitckens et al. 2005.

  5. Of Mice and Men

  6. Of Mice and Men

  7. ~60 kg Human flesh ~30g Mouse flesh ~2000X the number of cells

  8. Haploinsufficiency orLoss of Heterozygosity?

  9. Methods

  10. loxP loxP CRE LoxP LoxP Cre Routine or cis orientation of loxP sites results in fragment excision

  11. trans orientation of loxP sites results in reversible fragment inversion Pxol loxP CODING SEQUENCE CRE ECNEUQES GNIDOC LoxP PxoL CODING SEQUENCE Cre ECNEUQES GNIDOC

  12. You do the math. . . • Cre-mediated inversion yields 40% reverse orientation per trans-floxed allele • Homozygosity for trans-floxed alleles should yield 40% loss of total copies of functional gene across tissue • 20% of cells will remain unaffected and fwd/fwd • 20% of cells will end up fwd/fwd after inversion • 40% of cells will end up fwd/rev after inversion • 20% of cells will end up rev/rev after inversion

  13. Targeting Construct Intron 1 loxPexon 2loxP neo loxP intron 2exon 3 • Exon 2 contains two of the very few disease-causing missense mutations at highly conserved amino acid residues 339 and 340. • Exon 2 inversion not only disrupts the sequence, but introduces a stop codon in the reading frame

  14. Cre-Recombinase Driver • Doxycycline-inducible Collagen type II promoter-Cre • Doxycycline adminstered via maternal drinking water during second week of life Gover and Roughley et al., 2006

  15. Results

  16. PCR Testing with Multiple Primers Intron 1 loxPexon 2loxP neo loxP intron 2exon 3 • All permutations of flipping were present in every cartilage containing tissue.

  17. exon 2 neo exon 2 excised neo excised neo reversed exon 2 neo excised neo excised neo reversed neo exon 2 reversed exon 2 reversed reversed neo exon 2

  18. Effects of Cre-mediated inversion RT-PCR demonstrated the expected 40% reduction in Ext1 transcripts across homozygous tissue exposed to Cre

  19. Phenotype:Osteochondromas?

  20. Distal femur physis 6 week old Ext1 fl/fl with doxy-col2-Cre

  21. Proximal tibia 6 week old Ext1 fl/fl with doxy-col2-Cre

  22. # of mice with osteochondromas/ # of mice over 6 weeks old Genotype _____________________________________________ fl/fl+doxy-col2a1-Cre 12/12 fl/fl without Cre 0/5 wt/fl+doxy-col2a1-Cre 0/7 wt/fl without Cre 0/1 wt/wt without Cre 0/8 _______________________________

  23. Traditional Knockout 50% tissue reduction in Ext1 alleles Very rare biallelic loss Osteochondromas very rare Trans-floxed Conditional Knockout 40% tissue reduction in Ext1 alleles 20% biallelic loss Osteochondromas rampant Comparison

  24. Discussion Loss of heterozygosity is the mechanism of osteochondromagenesis in the setting of hereditary multiple exostoses

  25. Hypothesis Disruption of both Ext1 alleles in a physeal chondrocyte is sufficient to form an osteochondroma

  26. Alternate Hypothesis Disruption of both Ext1 alleles in some physeal chondrocytes is sufficient to derange signals and form osteochondromas

  27. Hypothesis vs. Alternate Hypothesis Are osteochondromas clonal (at least consistent) for reverse orientation of exon 2? On-going work with laser capture micro-dissection and insitu hybridization

  28. Conclusion Osteochondromageneis resulted from low-prevalence biallelic disruption of Ext1 in chondrocytes, modeling loss of heterozygosity with a unique twist on the standard conditional knock-out

  29. Project Funding Support • OREF Resident Research Award 2003 • Department of Orthopaedics and Rehabilitation, University of Iowa • Val C. Sheffield Genetics Laboratory Department of Orthopaedics and Rehabilitation University of Iowa Hospitals & Clinics

  30. Osteochondromagenesis:Loss of heterozygosity modeled via Cre-mediated inversion of the second exon of Ext1 in chondrocytes Department of Orthopaedics and Rehabilitation University of Iowa Hospitals & Clinics Kevin B. Jones, MD Charles Searby, BS Gail Kurriger, BS James Martin, PhD Peter J. Roughley, PhD Jose A. Morcuende, MD, PhD Joseph A. Buckwalter, MD, MS Val C. Sheffield, MD, PhD Connective Tissue Oncology Society London, UK Friday, 14 November 2008

More Related